Zoetis Inc. (ZTS) Financial Statements

Zoetis Inc.

ZTS · NYSE

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Total Revenue	$9.47B	$9.26B	$8.54B	$8.08B	$7.78B	$6.67B	$6.26B	$5.83B
Cost of Revenue	$2.67B	$2.72B	$2.56B	$2.45B	$2.30B	$2.06B	$1.99B	$1.91B
Selling, General & Administrative	$2.38B	$2.32B	$2.15B	$2.01B	$2.00B	$1.73B	$1.64B	$1.48B
Interest Expense	$222.00M	$225.00M	$239.00M	$221.00M	$224.00M	$231.00M	$223.00M	$206.00M
Other Income / (Expense)	$36.00M	$19.00M	$159.00M	-$40.00M	-$48.00M	-$17.00M	$57.00M	$83.00M
Income Before Taxes	$3.36B	$3.13B	$2.94B	$2.66B	$2.49B	$2.00B	$1.80B	$1.69B
Provision for Income Taxes	$687.00M	$637.00M	$596.00M	$545.00M	$454.00M	$360.00M	$301.00M	$266.00M
Net Income	$2.67B	$2.49B	$2.34B	$2.11B	$2.04B	$1.64B	$1.50B	$1.43B
Basic EPS	$6.03	$5.47	$5.08	$4.51	$4.29	$3.44	$3.14	$2.96
Diluted EPS	$6.02	$5.47	$5.07	$4.49	$4.27	$3.42	$3.11	$2.93
Basic Shares Outstanding	443.44M	454.20M	461.17M	468.89M	474.35M	475.50M	478.13M	483.06M
Diluted Shares Outstanding	443.83M	454.85M	462.27M	470.38M	476.72M	478.57M	481.79M	486.90M

Analyst Estimates

Period	Consensus EPS	Low	High	Estimates	Revisions
Dec 2026	$6.87	$6.80	$6.95	9	↑0 ↓2
Dec 2027	$7.35	$7.06	$7.72	10	↑0 ↓2
Dec 2028	$7.85	$7.37	$8.44	6	↑0 ↓0
Dec 2029	$8.08	$8.08	$8.08	1	↑0 ↓0

Forward estimates are the sell-side consensus reported by Nasdaq, not a metir forecast.

Symbol: ZTS
Type: Stock
Sector: Health Care
Industry: Biotechnology: Pharmaceutical Preparations
Country: North America
Exchange: NYSE

Zoetis is the world's leading animal health company, driven by a singular purpose: to nurture our world and humankind by advancing care for animals. With a legacy of nearly 75 years, Zoetis continues to pioneer ways to predict, prevent, detect, and treat animal illness, supporting veterinarians, livestock producers, and pet owners in over 100 countries. We integrate deep scientific expertise, data-driven R&D, advanced manufacturing, robust post marketing surveillance (PV), and commercial excellence to deliver meaningful innovation across medicines, vaccines, diagnostics, biopharmaceuticals, and digital solutions. Guided by our vision to be the most trusted and valued animal health company, Zoetis is committed to setting new standards for the future of animal care through innovation, customer obsession, and purpose-driven colleagues. To learn more, visit Zoetis.com.

Key Issues

Bullish view

Companion-animal products are a central focus ahead of the second-quarter report, and continued demand could support earnings growth.

Bearish view

The evidence identifies U.S. competition as a counterweight, potentially limiting growth even if companion-animal products remain a strategic strength.

Analyst Consensus

See all

Hold

16 analysts

$74

Current

—

Low

$97

Average

—

High

Average target implies +30.92% versus the current price.

Earnings History

BeatMissNo estimate

Peers

Royalty Pharma plc Class A Ordinary Shares